---
schema_version: "secwatch.filing_event.v1"
accession: "0001404644-26-000030"
form_type: "8-K"
ticker: "NGNE"
cik: "0001404644"
company_name: "Neurogene Inc."
filed_at: "2026-04-20T23:59:59+00:00"
generated_at: "2026-05-15T05:18:55.417955+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Neurogene appoints Christy Shafer as CCO, Christine Mikail to Board

## Summary
- Christy Shafer joins as CCO; previously SVP/GM at Avidity Biosciences and CCO at Marinus Pharmaceuticals.
- Shafer will lead commercial strategy and launch readiness for NGN-401 gene therapy for Rett syndrome.
- Christine Mikail, President and CFO, appointed to Board as Class II director through 2028 annual meeting.
- Mikail brings expertise in strategy, finance, and corporate development; no additional compensation for board role.
- Appointments position Neurogene for next phase of growth as it advances NGN-401 toward potential launch.

## SEC filing metadata
- accession: 0001404644-26-000030
- form_type: 8-K
- ticker: NGNE
- cik: 0001404644
- company_name: Neurogene Inc.
- filed_at: 2026-04-20T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404644/000140464426000030/0001404644-26-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404644/000140464426000030/ngne-20260420.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001404644-26-000030
- JSON: https://secwatch.observer/filing/0001404644-26-000030.json
- Plain text: https://secwatch.observer/filing/0001404644-26-000030.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.